1Denton CP, Black CM. Scleroderma--clinical and pathological advances[ J]. Best Pract Res Clin Rheumatol, 2004, 18 (3): 271-290.
2Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee [ J]. Arthritis Rheum, 1980, 23 (5): 581- 590.
3Steen VD, Medsger TA Jr, Osial TA Jr, et al. Factors predicting development of renal involvement in progressive systemic sclerosis [J]. AmJMed, 1984, 76(5):779-786.
4Steen VD, Costantino JP, Shapiro AP, et al. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors [ J ]. Ann Intern Med, 1990, 113(5) : 352-357.
5Seussel-Lonzetti L, Joyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival[ J ]. Medicine (Baltimore) , 2002, 81 (2) : 154-167.
7Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse seleroderma [ J ]. Arthritis Rheum, 2000, 43 (11) : 2437-2444.
8Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis [ J ]. Arthritis Rheum, 1998, 41(9) : 1613-1619.
9Teixeira L, Mouthon L, Mahr A, et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients[ J]. Ann Rheum Dis, 2008, 67 ( 1 ) : 110-116.
10Trang G, Steele R, Baron M, et al. Corticosteroids and the risk of scleroderma renal crisis: a systematic review[ J]. Rheumatol Int, 2012, 32(3) : 645-653.
